According to the South China Morning Post, Shinzo Abe opened up possibilities for the Trump administration to acquire the drug. The medicine may be less effective in severe cases of the disease where the virus has already multiplied.
Kulingana na South China Morning Post, Shinzo Abe amefanya mazungumzo ya awali na utawala wa Trump kuhusu kununua dawa hiyo. Dawa hiyo inaweza kuwa sio fanisi kwa ugonjwa kali ambapo virusi tayari vimeongezeka.